
This submission: Clinical Safety Update and PI/PIL reformat
Date of approval: 12 September 2021

Professional information for FUNGISTOP TOPICAL

SCHEDULING STATUS

S1

1. NAME OF THE MEDICINE

FUNGISTOP TOPICAL 1 % *m/m* cream

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1 g of cream contains 10 mg clotrimazole.

Excipients with known effect:

Preservatives:

Nipastat 0,275 % *m/m*

Imidurea 0,300 % *m/m*

For full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Cream.

A soft white cream.

This submission: Clinical Safety Update and PI/PIL reformat

Date of approval: 12 September 2021

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

1. All dermatomycoses due to dermatophytes (e.g. *Trichophyton* species).
2. All dermatomycoses due to yeasts (e.g. *Candida* species).
3. Dermatomycoses due to moulds and other fungi.
4. Skin disease with secondary infection by these fungi.

The dermatomycoses mentioned under 1 – 4 include among others:

- Mycoses of the skin and skin folds (e.g. fungal infections of the groin, perineum, axillae, Dhobies' or jock itch and barber's itch.)
- Ringworm.
- Interdigital mycoses e.g. athletes foot.
- *Candida vulvitis* (vulval thrush).
- *Candida balanitis* (thrush of the glans penis).
- Pityriasis (Tinea) versicolor.
- Erythrasma.
- Paronychia (associated with nail mycoses).

4.2 Posology and method of administration

Apply thinly to the affected areas 2 – 3 times daily and rub in. A small amount of cream is sufficient for an area about the size of the palm. Successful treatment demands that FUNGISTOP TOPICAL cream be applied correctly and over a sufficiently long period of time. The duration of treatment varies. In general, it is 3 – 4 weeks in the case of dermatomycoses due to dermatophytes and yeasts; in *Candida vulvitis* and *Candida balanitis*, 1 – 2 weeks; and approximately 2 – 4 weeks in

This submission: Clinical Safety Update and PI/PIL reformat**Date of approval:** 12 September 2021

erythrasma and 1 – 3 weeks in pityriasis versicolor.

Treatment of fungal infection should be continued for approximately 2 weeks after the disappearance of all symptoms despite a rapid subjective improvement, in order to prevent relapse.

Athletes foot: Always dry the feet carefully, especially between the toes.

FUNGISTOP TOPICAL cream is odourless, can be washed off and does not stain.

4.3 Contraindications

Hypersensitivity to clotrimazole or any of the excipients of FUNGISTOP TOPICAL (see section 6.1).

4.4 Special warnings and precautions for use

For external use only. Not for ophthalmic use.

FUNGISTOP TOPICAL contains cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis).

4.5 Interaction with other medicines and other forms of interaction

FUNGISTOP TOPICAL may cause damage to latex contraceptives.

Consequently the effectiveness of such contraceptives may be reduced. Patients should be advised to use alternative precautions for at least five days after using FUNGISTOP TOPICAL.

This submission: Clinical Safety Update and PI/PIL reformat**Date of approval:** 12 September 2021

4.6 Fertility, pregnancy and lactation

Safety and efficacy of FUNGISTOP TOPICAL in pregnancy and lactation have not been established.

4.7 Effects on ability to drive and use machines

FUNGISTOP TOPICAL cream has no or negligible influence on the ability to drive or use machines.

4.8 Undesirable effects

Immune system disorders

Allergic reaction (syncope, hypotension, dyspnoea, urticaria)

Skin and subcutaneous tissue disorders

Blisters, discomfort/pain, oedema, erythema, irritation, peeling/exfoliation, pruritis, rash, stinging/burning.

Contact allergic dermatitis can occur. If this occurs, treatment should be discontinued.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are asked to

This submission: Clinical Safety Update and PI/PIL reformat

Date of approval: 12 September 2021

report any suspected adverse reactions to SAHPRA via the “**Adverse Drug Reactions Reporting Form**”, found online under SAHPRA’s publications:

<https://www.sahpra.org.za/Publications/Index/8>.

4.9 Overdose

See section 4.8. In case of accidental ingestion, gastrointestinal disturbances and central nervous system depression may occur. Treatment is symptomatic and supportive.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Category and class: A 20.2.2 Fungicides.

Pharmacotherapeutic group: Antifungals for topical use – imidazole and triazole derivatives

ATC code: D01AC01

Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the fungal cytoplasmic membrane.

Clotrimazole has a broad antimycotic spectrum of action *in vitro* and *in vivo*, which includes dermatophytes, yeasts and moulds.

5.2 Pharmacokinetic properties

Pharmacokinetic investigations after dermal application have shown that clotrimazole is minimally

This submission: Clinical Safety Update and PI/PIL reformat**Date of approval:** 12 September 2021

absorbed from the intact or inflamed skin into the human blood circulation. The resulting peak serum concentrations of clotrimazole were below the detection limit of 0,001 µg/ml, suggesting that clotrimazole applied topically is unlikely to lead to measurable systemic effects or side effects

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Propylene glycol

Purified water

Imidurea

Nipastat

Liquid paraffin

Cremophor A25

Cremophor A6

Cetostearyl alcohol.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months.

This submission: Clinical Safety Update and PI/PIL reformat

Date of approval: 12 September 2021

6.4 Special precautions for storage

Store at or below 25 °C in a well closed container, protected from light.

6.5 Nature and contents of container

20 g printed aluminium tube in an outer carton.

6.6 Special precautions for disposal and other handling

No special requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION

Biotech Laboratories (Pty) Ltd

Ground Floor, Block K West, Central Park

400 16th Road, Randjespark, Midrand 1685

South Africa

8. REGISTRATION NUMBER

27/20.2.2/0337

This submission: Clinical Safety Update and PI/PIL reformat

Date of approval: 12 September 2021

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

August 1992

10. DATE OF REVISION OF THE TEXT

14 July 2021 - revised

12 September 2021 - approved